Loading...
SIEB is not a good buy right now for an impatient investor. The technical setup is still bearish (down-trending moving averages and negative MACD), there are no proprietary buy signals today, and the latest quarter shows revenue growth but sharply weaker profitability—so the risk/reward for buying immediately is unattractive. A better approach is to wait for a confirmed break above near-term resistance (~3.09–3.20) or a cleaner reversal signal.
Trend/structure: Bearish alignment (SMA_200 > SMA_20 > SMA_5) indicates the broader trend is still down. Momentum: MACD histogram at -0.023 is below zero but negatively contracting, suggesting downside momentum is easing (early stabilization) rather than clearly reversing up. RSI: RSI_6 at ~51.7 is neutral—no oversold bounce signal. Levels: Pivot 2.926 is the key line; holding above it keeps the stock in a near-term base attempt. Resistance sits at R1 3.093 then R2 3.195; price (3.01) is below R1, meaning upside is capped until a breakout. Support is S1 2.76 then S2 2.658 if the pivot fails. Pattern-based outlook provided: 70% chance of ~-0.3% next day, ~-0.62% next week, and +2.64% next month—near-term drift slightly negative with only modest monthly upside.

Options open-interest skew is bullish (more calls than puts), suggesting some market participants are positioned for upside. Revenue grew strongly in the latest reported quarter (2025/Q3 +18.62% YoY), indicating top-line momentum. MACD downside momentum is easing (negative but contracting), which can precede a base/reversal if price can reclaim resistance.
and price is still below key resistance (3.09–3.20). Profitability deteriorated significantly in 2025/Q3: net income -57.61% YoY and EPS -60% YoY, undermining confidence in quality of growth. News flow provided is more human-interest/industry narrative (wealth management career/profile) than a clear event-driven catalyst likely to re-rate the stock near-term. Hedge fund and insider trading trends are neutral (no supportive accumulation signal).
Latest quarter: 2025/Q3. Revenue increased to 25.701M (+18.62% YoY), showing solid top-line growth. However, net income fell to 1.622M (-57.61% YoY) and EPS declined to 0.04 (-60.00% YoY), indicating margins/expenses or non-operating impacts pressured earnings. Overall: growth is present, but earnings quality and profitability trend are negative in the latest quarter, which weakens the immediate bull case.
No analyst rating or price target change data was provided, so a recent trend summary cannot be confirmed. With the available information, Wall Street pros/cons cannot be reliably tallied; the actionable takeaway is that conviction signals must come from price action/earnings trajectory instead—both of which are currently mixed-to-bearish.
